RecruitingPhase 2NCT06814145
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Sotatercept(biological)
- Enrollment
- 130 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Pulmonary Associates, PA ( Site 1008), Phoenix, Arizona, United States
- Jeffrey S. Sager, MD Medical Corporation ( Site 1060), Santa Barbara, California, United States
- Stanford University Medical Center ( Site 1024), Stanford, California, United States
- South Denver Cardiology Associates ( Site 1091), Littleton, Colorado, United States
- Yale New Haven Hospital ( Site 1093), New Haven, Connecticut, United States
- AdventHealth Orlando ( Site 1058), Orlando, Florida, United States
- The Emory Clinic ( Site 1030), Atlanta, Georgia, United States
- Norton Pulmonary Specialists ( Site 1066), Louisville, Kentucky, United States
- University Of Nebraska Medical Center ( Site 1053), Omaha, Nebraska, United States
- Weill Cornell Medical Center ( Site 1046), New York, New York, United States
- Duke University Medical Center ( Site 1026), Durham, North Carolina, United States
- The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001), Cincinnati, Ohio, United States
- The Cleveland Clinic Foundation. ( Site 1065), Cleveland, Ohio, United States
- The Ohio State University Wexner Medical Center ( Site 1032), Columbus, Ohio, United States
- Allegheny General Hospital ( Site 1088), Pittsburgh, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06814145 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGNANCT07366879Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial HypertensionGolden Jubilee National Hospital
- RECRUITINGPHASE3NCT07245680COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →